Sign In
Last checked at 
17 Feb 2026 15:30
GSK plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Maya Martinez-Davis | |||
b) | Position/status | President, US | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADS')
ISIN: US37733W2044 | |||
b) | Nature of the transaction | The vesting of awards granted in 2020 under the Company's 2017 Performance Share Plan following a voluntary 3-year deferral | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$0.00 | 10,836.957 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2026-02-13 | |||
f) | Place of the transaction
| N/A | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Maya Martinez-Davis | |||
b) | Position/status | President, US | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADS')
ISIN: US37733W2044 | |||
b) | Nature of the transaction | The sale of ADS to meet tax liabilities on the vesting of awards granted in 2020 under the Company's 2017 Performance Share Plan following a voluntary 3-year deferral
| |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$58.8509 | 4,009.778 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2026-02-13 | |||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
Follow the stocks
